MiNK Therapeutics, Inc. (INKT)
| Previous close | 0.9300 |
| Open | 0.9500 |
| Bid | 0.8536 x 100 |
| Ask | 0.9518 x 100 |
| Day's range | 0.8801 - 0.9500 |
| 52-week range | 0.7500 - 1.9600 |
| Volume | |
| Avg. volume | 160,993 |
| Market cap | 35.368M |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5900 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
ZacksMiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlobeNewswireMiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will st
- GlobeNewswire
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These
